Bellerophon plunges as lung disease treatment fails in late-stage study

Bellerophon Therapeutics

05/06/2023 13:48

** Shares of drug developer Bellerophon Therapeutics Inc
 BLPH.O  plummet 74% to $1.85 premarket, among top pct. losers
across U.S. exchanges
    ** Co says its delivery system INOpulse did not meet the
main goal in a late-stage study for patients with a type of lung
disease
    ** Adds that it does not see a path forward for continuing
the trial
    ** The main goal of the study was related to the change in
moderate to vigorous physical activity as measured by
actigraphy, a method of monitoring human rest/activity cycles,
after 16 weeks of chronic treatment
    ** Co's INOpulse is a proprietary pulsatile nitric oxide
delivery system which is being studied for the treatment of
fibrotic interstitial lung disease
   ** Up to last close, stock up ~684% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))